BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 19304409)

  • 21. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy.
    Li YX; Liu QF; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Liu XF; Zhou LQ; Yu ZH
    Cancer; 2011 Nov; 117(22):5203-11. PubMed ID: 21523771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type.
    Zhao T; Li YX; Wang SL; Jin J; Wang WH; Song YW; Liu YP; Liu XF; Fang H; Ren H; Chen B; Qi SN; Liu QF; Lu NN; Yu ZH
    Ann Hematol; 2013 Mar; 92(3):325-32. PubMed ID: 23100164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
    Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
    Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.
    Kim HJ; Bang SM; Lee J; Kwon HC; Suh C; Kim HJ; Lee JH; Ryoo BY; Park YH; Kwon JM; Oh SY; Lee HR; Kim K; Jung CW; Park K; Kim WS
    Bone Marrow Transplant; 2006 May; 37(9):819-24. PubMed ID: 16547486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
    Ballonoff A; Rusthoven KE; Schwer A; McCammon R; Kavanagh B; Bassetti M; Newman F; Rabinovitch R
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1465-71. PubMed ID: 18495371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
    Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
    Cui XZ; Wang HQ; Liu XM; Zhang HL; Li W
    Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):609-11. PubMed ID: 18246818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Shim SJ; Yang WI; Shin E; Koom WS; Kim YB; Cho JH; Suh CO; Kim JH; Kim GE
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):31-8. PubMed ID: 17049184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
    Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
    Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
    Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
    J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
    Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent chemoradiotherapy for limited-stage extranodal natural killer/t-cell lymphoma, nasal type.
    Shimada K; Suzuki R
    J Clin Oncol; 2010 May; 28(14):e229; author reply e230. PubMed ID: 20351319
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type.
    Wang B; Li XQ; Ma X; Hong X; Lu H; Guo Y
    Am J Hematol; 2008 Oct; 83(10):795-9. PubMed ID: 18756548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
    Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
    Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
    Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
    Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.